131 related articles for article (PubMed ID: 26091641)
1. Sensitivity and Specificity of the In Vitro Guinea Pig Papillary Muscle Action Potential Duration for the Assessment of Drug-Induced Torsades De Pointes Liability in Humans.
Ducroq J
Handb Exp Pharmacol; 2015; 229():205-19. PubMed ID: 26091641
[TBL] [Abstract][Full Text] [Related]
2. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
Lee N; Authier S; Pugsley MK; Curtis MJ
Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
[TBL] [Abstract][Full Text] [Related]
3. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
Hashimoto K
Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
[TBL] [Abstract][Full Text] [Related]
4. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
Tabo M; Kimura K; Ito S
J Pharmacol Toxicol Methods; 2007; 55(3):254-61. PubMed ID: 17229580
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
6. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
Guns PJ; Johnson DM; Weltens E; Lissens J
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
[TBL] [Abstract][Full Text] [Related]
8. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity.
De Clerck F; Van de Water A; D'Aubioul J; Lu HR; van Rossem K; Hermans A; Van Ammel K
Fundam Clin Pharmacol; 2002 Apr; 16(2):125-40. PubMed ID: 12031065
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.
Aubert M; Osterwalder R; Wagner B; Parrilla I; Cavero I; Doessegger L; Ertel EA
Drug Saf; 2006; 29(3):237-54. PubMed ID: 16524323
[TBL] [Abstract][Full Text] [Related]
10. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
11. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
12. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Pugsley MK; Curtis MJ; Hayes ES
Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
[TBL] [Abstract][Full Text] [Related]
13. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model.
Morissette P; Nishida M; Trepakova E; Imredy J; Lagrutta A; Chaves A; Hoagland K; Hoe CM; Zrada MM; Travis JJ; Zingaro GJ; Gerenser P; Friedrichs G; Salata JJ
J Pharmacol Toxicol Methods; 2013; 68(1):137-49. PubMed ID: 23649000
[TBL] [Abstract][Full Text] [Related]
14. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
[TBL] [Abstract][Full Text] [Related]
15. The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research.
Van Deuren B; Van Ammel K; Somers Y; Cools F; Straetemans R; van der Linde HJ; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):11-23. PubMed ID: 19422925
[TBL] [Abstract][Full Text] [Related]
16. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
[TBL] [Abstract][Full Text] [Related]
17. QT PRODACT: evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles.
Kii Y; Hayashi S; Tabo M; Shimosato T; Fukuda H; Itoh T; Amano H; Saito M; Morimoto H; Yamada K; Kanda A; Ishitsuka T; Yamazaki T; Kiuchi Y; Taniguchi S; Mori T; Shimizu S; Tsurubuchi Y; Yasuda S; Kitani S; Shimada C; Kobayashi K; Komeno M; Kasai C; Hombo T; Yamamoto K
J Pharmacol Sci; 2005; 99(5):449-57. PubMed ID: 16493186
[TBL] [Abstract][Full Text] [Related]
18. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
Guo L; Dong Z; Guthrie H
J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs.
Kågström J; Sjögren EL; Ericson AC
J Pharmacol Toxicol Methods; 2007; 56(2):186-93. PubMed ID: 17582787
[TBL] [Abstract][Full Text] [Related]
20. Assessment of QT liabilities in drug development.
Arrigoni C; Crivori P
Cell Biol Toxicol; 2007 Jan; 23(1):1-13. PubMed ID: 17013551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
